文献速递呼吸危重症与机械通气呼吸道感染肺栓塞与肺血管病

肥胖对危重症的影响

Impact of Obesity in Critical Illness.
PubMed 文献 · Chest · 2021-08-05

肥胖患病率全球上升,脂肪组织对危重症有重要影响。呼吸力学改变可致呼气限流、肺不张和通气血流比失调引起低氧血症,肥胖低通气综合征可致高碳酸血症。插管可能因面罩通气和围插管低氧血症而复杂化。肥胖增加ARDS风险,应按预测体重行肺保护性通气。部分研究显示肥胖与危重症生存改善相关,但机制不明。

要点

  • 肥胖患者插管风险高,需警惕面罩通气和围插管低氧血症。
  • 肥胖增加ARDS风险,应基于预测体重行肺保护性通气。
  • 肥胖与VTE和感染风险增加相关,需适当预防性抗凝和早期拔除导管。

核心结论

  • 肥胖通过呼吸力学、通气需求和合并症等影响危重症病程,并与部分研究中危重症生存改善相关,但机制未明。
  • 肥胖与SARS-CoV-2感染中插管和死亡风险增加相关。

研究设计与样本

  • 本文为综述,未报告系统检索范围或样本量。

主要发现

  • 呼吸力学改变导致呼气限流、肺不张和V̇/Q̇失调,引起低氧血症;呼吸做功改变和肥胖低通气综合征可致高碳酸血症。
  • 肥胖患者ARDS风险增加,应基于预测体重行肺保护性通气。
  • 增加PEEP联合适当体位可能克服肺泡去复张和内源性PEEP,但高PEEP策略对结局的影响证据不足。
  • 肥胖患者可安全实施静脉-静脉体外膜氧合。
  • 肥胖与VTE和感染风险增加相关,预防性抗凝适当剂量和早期拔除留置导管可降低风险。

关键数值与推荐

  • 肺保护性通气应基于预测体重设置潮气量。
  • 液体管理需考虑慢性心肾疾病患病率增加、血容量扩张和急性肾损伤风险升高。
  • 药物药效学和药代动力学可能因疏水性药物分布至脂肪库及合并肝肾病而改变。

临床怎么用

  • 对肥胖危重症患者插管时应预见面罩通气和围插管低氧血症困难。
  • ARDS患者按预测体重行肺保护性通气,可考虑增加PEEP联合体位。
  • 加强VTE和感染预防,适当剂量预防性抗凝并早期拔除留置导管。
  • 液体管理和药物剂量需考虑肥胖相关合并症及药代动力学改变。

局限性

  • 高PEEP策略对结局影响的证据不足。
  • 肥胖与危重症生存改善的关联是否为保护效应或观察性研究固有局限尚不清楚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The prevalence of obesity is rising worldwide. Adipose tissue exerts anatomic and physiological effects with significant implications for critical illness. Changes in respiratory mechanics cause expiratory flow limitation, atelectasis, and V̇/Q̇ mismatch with resultant hypoxemia. Altered work of breathing and obesity hypoventilation syndrome may cause hypercapnia. Challenging mask ventilation and peri-intubation hypoxemia may complicate intubation. Patients with obesity are at increased risk of ARDS and should receive lung-protective ventilation based on predicted body weight. Increased positive end expiratory pressure (PEEP), coupled with appropriate patient positioning, may overcome the alveolar decruitment and intrinsic PEEP caused by elevated baseline pleural pressure; however, evidence is insufficient regarding the impact of high PEEP strategies on outcomes. Venovenous extracorporeal membrane oxygenation may be safely performed in patients with obesity. Fluid management should account for increased prevalence of chronic heart and kidney disease, expanded blood volume, and elevated acute kidney injury risk. Medication pharmacodynamics and pharmacokinetics may be altered by hydrophobic drug distribution to adipose depots and comorbid liver or kidney disease. Obesity is associated with increased risk of VTE and infection; appropriate dosing of prophylactic anticoagulation and early removal of indwelling catheters may decrease these risks. Obesity is associated with improved critical illness survival in some studies. It is unclear whether this reflects a protective effect or limitations inherent to observational research. Obesity is associated with increased risk of intubation and death in SARS-CoV-2 infection. Ongoing molecular studies of adipose tissue may deepen our understanding of how obesity impacts critical illness pathophysiology.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Anderson MR, Shashaty MGS. Impact of Obesity in Critical Illness. Chest. 2021. PMID: 34364868. doi:10.1016/j.chest.2021.08.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。